Matinas Biopharma (MTNB) Stock Price, News & Analysis

Company Overview

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.

Key Stats

• Today's Range: $0.57 to $0.99
• 50-Day Range: $0.19 to $0.96
• 52-Week Range: $0.48 to $21.50
• Volume: 13.10 million shs
• Average Volume: 2.14 million shs
• Market Capitalization: $3.56 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

MTNB Stock Analysis - Frequently Asked Questions

How have MTNB shares performed this year?

Matinas Biopharma's stock was trading at $0.51 at the beginning of the year. Since then, MTNB stock has increased by 37.3% and is now trading at $0.70.
View the best growth stocks for 2025 here.

How were Matinas Biopharma's earnings last quarter?

Matinas Biopharma Holdings, Inc. (NYSE:MTNB) announced its quarterly earnings results on Wednesday, August, 14th. The company reported ($0.02) earnings per share for the quarter, hitting the consensus estimate of ($0.02).

How do I buy shares of Matinas Biopharma?

Shares of MTNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Matinas Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Matinas Biopharma investors own include AcelRx Pharmaceuticals (ACRX), DURECT (DRRX), Kosmos Energy (KOS), Strongbridge Biopharma (SBBP), Selecta Biosciences (SELB), Acasti Pharma (ACST) and Abeona Therapeutics (ABEO).

Company Calendar

• Last Earnings: 8/14/2024
• Today: 1/15/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:MTNB
• Previous Symbol: NYSE:MTNB
• CUSIP: N/A
• CIK: 1582554
• Web: N/A
• Phone: (908) 484-8805
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($4.85)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-22,940,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -123.06%
• Return on Assets: -94.28%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.53
• Quick Ratio: 5.53

Sales & Book Value

• Annual Sales: $1.10 million
• Price / Sales: 3.24
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.43 per share
• Price / Book: 0.16

Miscellaneous

• Outstanding Shares: 5,087,000
• Free Float: 4,599,000
• Market Cap: $3.56 million
• Optionable: N/A
• Beta: 1.61